Therapeutic Agents for the Treatment of Tumors in the CNS
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: 25 May 2024 | Viewed by 3156
Special Issue Editors
2. Genentech Inc., San Francisco, CA, USA
Interests: CNS drug delivery; oncology; pharmacokinetics/pharmacodynamics (PK/PD)
Interests: gliomas; clinical trials; CNS malignancies
Special Issue Information
Dear Colleagues,
This Special Issue aims to create a platform for the exchange of ideas and findings related to treatments for tumors in the central nervous system (CNS). The current shortage of disease-modifying treatments for patients with both primary and metastatic brain tumors represents one of the most significant unmet needs of our time. Our ability to effectively tap into otherwise-promising anti-cancer therapies is challenged by the blood–brain barrier, which severely restricts the entry of systemic/orally delivered therapeutic agents into the brain. We seek innovative thoughts, research, and approaches to tackling critical questions relevant to the treatment of debilitating brain tumors.
We welcome contributions at the forefront of basic and translational neuro-oncology with potential to improve the diagnosis and treatment of tumors in the brain. This Special Issue aims to highlight the latest advances in treatments with transformative potential in neuro-oncology from experts in relevant fields such as pharmaceutical sciences, neuroscience, pharmacology, medical oncology, drug delivery, and clinical neuro-surgery. Along with original research articles, we encourage authors to submit comprehensive up-to-date reviews that detail the current status of these treatments and that provide perspectives or future directions. We aim to help the scientific community in finding better treatment options for patients afflicted with devastating CNS tumors.
Dr. Gautham Gampa
Dr. Sani H. Kizilbash
Dr. Shannon P. Fortin Ensign
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- primary brain tumors
- glioblastoma
- brain metastases (BMs)
- neuro-oncology
- blood–brain barrier (BBB)
- drug delivery
- preclinical PK/PD
- molecularly targeted agents
- immunotherapy
- new modalities
